Neuphoria Therapeutics Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Neuphoria Therapeutics Inc. (NEUP) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$2.58 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-09-18
- Neuphoria Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$515.13K, a 122.74% decline year-over-year.
- Neuphoria Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$1.18M, a 414.08% decline year-over-year.
- Neuphoria Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$1.60M.
- Neuphoria Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $718.26K.
- Neuphoria Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2026 was -$2.58M, a 273.48% decline from fiscal 2025.
- Neuphoria Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $1.49M, a 435.05% increase from fiscal 2024.
- Neuphoria Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $277.85K, a 101.23% increase from fiscal 2023.
- Neuphoria Therapeutics Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $138.08K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$515.13K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$1.69M derived: sum of 2 quarters · filed 2026-09-18 | -$3.30M derived: sum of 3 quarters · filed 2026-09-18 | -$2.58M 10-K · filed 2026-09-18 |
| 2026-03-31 | -$1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$2.78M derived: sum of 2 quarters · filed 2026-05-15 | -$2.06M 10-Q · filed 2026-05-15 | $201.13K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$884.48K 10-Q · filed 2026-02-17 | $1.38M derived: sum of 3 quarters · filed 2026-09-18 | $1.76M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | $718.26K 10-Q · filed 2025-11-14 | $2.98M derived: sum of 2 quarters · filed 2026-09-18 | $3.36M derived: sum of 3 quarters · filed 2026-09-18 | $2.57M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $2.64M derived: sum of 2 quarters · filed 2026-09-18 | $1.85M derived: sum of 3 quarters · filed 2026-09-18 | $1.49M 10-K · filed 2026-09-18 |
| 2025-03-31 | $375.53K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$410.85K derived: sum of 2 quarters · filed 2026-05-15 | -$778.43K 10-Q · filed 2026-05-15 | -$279.52K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$786.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$1.15M 10-Q · filed 2026-02-17 | -$655.05K derived: sum of 3 quarters · filed 2026-02-17 | -$1.13M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$367.58K 10-Q · filed 2025-11-14 | $131.32K derived: sum of 2 quarters · filed 2025-11-14 | -$342.78K derived: sum of 3 quarters · filed 2025-11-14 | $615.02K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $498.91K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $24.80K derived: sum of 2 quarters · filed 2025-09-29 | $982.60K derived: sum of 3 quarters · filed 2025-09-29 | $277.85K 10-K · filed 2025-09-29 |
| 2024-03-31 | -$474.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-20 | $483.69K derived: sum of 2 quarters · filed 2025-05-20 | -$221.05K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | $957.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | $253.06K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | -$704.75K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $138.08K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |